Zurcher Kantonalbank Zurich Cantonalbank Sells 387 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,640 shares of the biotechnology company’s stock after selling 387 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Arcturus Therapeutics were worth $241,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. New York State Teachers Retirement System purchased a new stake in Arcturus Therapeutics during the third quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. raised its holdings in Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,406 shares during the period. Arizona State Retirement System bought a new stake in Arcturus Therapeutics in the fourth quarter worth $211,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Arcturus Therapeutics by 5.9% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after buying an additional 606 shares during the period. Finally, Stratos Wealth Partners LTD. bought a new position in Arcturus Therapeutics during the third quarter valued at $301,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $27.32 on Tuesday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $17.52 and a fifty-two week high of $43.81. The company has a market cap of $735.73 million, a PE ratio of -26.27 and a beta of 2.65. The business’s 50-day simple moving average is $32.47 and its two-hundred day simple moving average is $30.07.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. The company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. As a group, analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.83 EPS for the current fiscal year.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total transaction of $299,860.65. Following the sale, the chief operating officer now directly owns 490,883 shares of the company’s stock, valued at approximately $17,185,813.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Citigroup boosted their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.33.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.